Skip to main content
International Journal of Clinical and Experimental Pathology logoLink to International Journal of Clinical and Experimental Pathology
. 2015 May 1;8(5):5793–5797.

RET polymorphisms might be the risk factors for thyroid cancer

Rui-Xue Huang 1, Fei Yang 1
PMCID: PMC4503170  PMID: 26191299

Abstract

Aims: The purpose of the study is to investigate the relationship between rs1799939, rs1800858 and rs74799832 polymorphisms of RET with thyroid cancer (TC) susceptibility. Methods: Genotypes distribution of control groups were tested by Hardy-Weinberg equilibrium (HWE). Rs1799939, rs1800858 and rs74799832 polymorphisms of RET were researched in 135 patients with TC and 135 healthy people using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Odds ratio (OR) with 95% confidence interval (CI) were calculated to evaluate the association between RET polymorphisms and the risk of TC by Chi-squared test. Results: Genotypes frequencies of the control group were consistent with HWE. The frequency of genotype AA and allele A in rs1799939 were significantly higher in patients with TC than controls (OR=3.768, P=0.046; OR=1.695, P=0.035). Genotype GG and allele G of rs1800858 remarkably increased the risk of TC (OR=2.149, P=0.039; OR=1.45, P=0.039). Moreover, CC genotype and C allele in rs74799832 polymorphism was related with TC susceptibility. (OR=2.28, P=0.049; OR=1.566, P=0.049). Conclusion: In present result, RET rs1799939, rs1800858 and rs74799832 polymorphisms might be the risk factors for TC.

Keywords: RET, polymorphisms, thyroid cancer

Introduction

Thyroid cancer (TC), common in endocrine system, is one of the malignant tumors with fast growth [1], which includes papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC). Among 80% of TC is PTC, the second is FTC (10%-15%) [2]. With rapid economic development, changes in diet and improvement of health-care, occurrence of TC, however, shows an upward tendency [3]. Previous study showed genetic and environmental factors were relative with the pathogenesis of TC [4]. The possible relevant environmental factors contain ionizing radiation [5], the anomaly uptake of iodine [6], estrogen [7], lesions in thyroid itself [8], other diseases [9,10], TSH and its receptors [11], the popularization of neck ultrasound [12] as well as social and cultural factors [13]. Moreover, many researches have demonstrated the close correlation of thyroid cancer with some internal oncogenes [14-17], such as RAS, BRAF, MYC, CCND1, RET. RET proto-oncogene encodes one of the receptor tyrosine kinase proteins [18], which is located on chromosome 10q11.2 including 24 exons [19]. It can transform signals for cell proliferation and differentiation as cell-surface molecules [20]. The high prevalence of RET cytogenetic rearrangement is a genetic lesion for the development of diseases, such as papillary thyroid carcinoma (PTC) [21], lung adenocarcinomas [22]. The mutations in RET are also the pathogenic factors and relevant with occurrence and development of some malignant tumors [23,24]. In view of the functions, a mass of publications reported the influence of RET gene on TC. The evidence showed that RET mutations were related with pathogenesis of MTC [25].

In present study, 135 patients with TC and 135 TC-free controls were enrolled to evaluate the association of RET rs1799939, rs1800858 and rs74799832 polymorphisms with the risk of TC.

Materials and methods

Objects of the study

A case-control study was conducted, containing 135 patients with TC and 135 healthy controls. Among patients, there were 89 males and 46 females with a median age of 55. The cases were confirmed by histopathology and did not experience radiotherapy or chemotherapy before blood collection.

Controls with a median age of 51 were collected within those for health physical examination in hospitals at same period, including 93 males and 42 females. People were excluded if they had family history of tumors, suffered from genetic diseases or other diseases related to thyroid. There were no significant differences in basic information like age, gender, race and native place between two groups through statistical test. This research was approved by the Research Ethics Committee of the hospital, and they all signed informed consent before the study and all subjects were not related by blood.

DNA extraction

5 mL peripheral venous blood was collected from every subject, conducted anticoagulant using ethylene diamine tetraacetic acid (EDTA) and preserved in refrigerator at -80°C. DNA was extracted by phenol-chloroform method according to instructions, and stored at -20°C for later.

Genotyping methods

Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to test genotypes distribution of RET rs1799939, rs1800858 and rs74799832 polymorphisms. The PCR primers were all designed by Primer 5.0 software and synthesized by Shanghai Genecore Biotechnologies Company (Table 1). Total of 25 µl PCR reaction mixtures included 2.0 µL template DNA, each 1.0 µL (10 µmol·L-1) of forward and reverse primers, 12.5 µL Master Mix and 8.5 µL of sterile water. PCR process consisted of the following steps: pre-denaturation at 94°C for 5 min, 35 cycles of denaturation at 94°C for 40 s, annealing at 62°C for 40 s and extension at 74°C for 30 s, finally continuation at 72°C for 10 min after all cycles. PCR products were digested by Bal I, Hal III and Sma I and measured each genotype of genetic variation through agarose gel electrophoresis.

Table 1.

Primers sequences in RET polymorphisms

Polymorphisms Up-/down-primer Sequences
rs1799939 Forward 5’-TGCTACCACAAGTTTGCCCA–3’
Reverse 5’-GGGCAAACTTGTGGTAGCAG–3’
rs1800858 Forward 5’-AAGCCTTATTCTCACCATCC–3’
Reverse 5’-AGGCTTCTTCAAGGACAAAA–3’
rs74799832 Forward 5’-GTTCTGTGCCCAGGAGTGTC–3’
Reverse 5’-CTGTAGACACTCCTGGGCAC–3’

Statistical analysis

The genotypes frequencies of the control group were tested whether it was correspond with Hardy-Weinberg equilibrium (HWE). Odds ratio (OR) with 95% confidence interval (CI) were calculated by χ2 test to examine the differences on genotype and allele distributions of each polymorphism between cases and controls using SPSS 18.0 software (P<0.05 represented the statistically significant differences).

Results

HWE test

The HWE test in controls showed that the goodness of fit to the law in each site was fine (P>0.05), indicating that controls were in equilibrium state and had good representativeness.

Analysis on the correlation of RET alleles and genotypes with TC patients

Genotypes distributions of rs1799939, rs1800858 and rs74799832 polymorphisms in RET showed that (Table 2) AA genotype and A allele of rs1799939 polymorphism significantly increased the risk of thyroid cancer (OR=3.768, 95% CI=1.006-14.111; OR=1.695, 95% CI=1.061-2.708), the genotype and allele frequencies of GG and G in rs1800858 were higher in cases than controls (OR=2.149, 95% CI=1.078-4.285; OR=1.450, 95% CI=1.033-2.036). CC genotype and C allele in rs74799832 were the risk factors for thyroid cancer (OR=2.280, 95% CI=1.018-5.109; OR=1.566, 95% CI=1.078-2.275).

Table 2.

Relationship between three polymorphisms of RET with TC risk

Genotype/allelotype Cases (n=135) Controls (n=135) χ2 P value OR (95% CI)
rs1799939
    GG 92 104 - - 1
    GA 33 28 0.96 0.38 1.33 (0.75-2.37)
    AA 10 3 4.39 0.046 3.77 (1.01-14.11)
    G 217 (80.4%) 236 (87.4%) - - 1
    A 53 (19.6%) 34 (12.6%) 4.95 0.035 1.70 (1.06-2.71)
rs1800858
    AA 24 39 - - 1
    AG 70 65 3.26 0.093 1.75 (0.95-3.22)
    GG 41 31 4.78 0.038 2.15 (1.08-4.29)
    A 118 (43.7%) 143 (53.0%) - - 1
    G 152 (56.3%) 127 (47.0%) 4.64 0.039 1.45 (1.03-2.04)
rs74799832
    TT 63 79 - - 1
    TC 52 45 1.97 0.19 1.45 (0.86-2.43)
    CC 20 11 4.14 0.049 2.28 (1.02-5.11)
    T 178 (65.9%) 203 (75.2%) - - 1
    C 92 (34.1%) 67 (24.8%) 5.57 0.023 1.57 (1.08-2.28)

Discussion

For thyroid cancer, it has been demonstrated that incidence of the disease is higher in females than in males [26] and increases with aging [27]. So far, many therapies are applied for treatment of TC, such as surgery, chemotherapy, endocrine and radioactive therapies, but the results were unsatisfactory [28]. Genes associated with TC are inevitable objects in study. The study of Lee et al. demonstrated that IL17RA polymorphisms are associated with both development and bilaterality of PTC in Korean population [29]. Wei et al. has uncovered the expression level of mir-149-5p has an influence on local progression of PTC and susceptibility in Chinese populations [30]. In research of Chen et al., ECRG4 could regulate cell cycle in PTC cells which transit from the G1 to G2 phase and promote tumors growth [31].

RET is a proto-oncogene encoding receptor thyroid kinase protein. Researches show that RET rearrangement is one of the most common types of gene modification in PTC [32], and is related to the incidence of radioactive TC [33]. RET mutants are common in MTC [34,35]. In recent years, many studies have discussed the relationship of RET polymorphisms with thyroid cancer. According to the study of Santos et al., minor alleles of RET G691S and S904S polymorphisms significantly increase tumors size in patients with TC at diagnosis, and S836S polymorphism is a risk factor for PTC, but not FTC [36]. A result that RET polymorphisms have an additive influence on evaluating the risk of MTC metastasis was found by Lucieli et al [37]. Ho et al. has reported that RET exon 7 (and possibly 14) polymorphism is a risk factor increased the morbidity of differentiated TC (DTC) [38].

In our case-control study, three polymorphisms of RET (rs1799939, rs1800858 and rs74799832) were selected to explore the correlation with pathogenesis of TC. The mutant hemozygous genotype AA and A allele of RET rs1799939 polymorphisms significantly increased the risk of TC. The results reported from many publications were consistent with ours. Cardot et al. research demonstrated RET G691S (rs1799939) variant was an independent predictor with a high basal calcitonin synthesis rate for sporadic MTC (sMTC) [39]. A meta-analysis of Lantieri et al. have uncovered G691S mutant allele can increase the risk of MTC, especially in females [40]. The same as rs1799939 polymorphism, the frequencies of genotype GG and allele G in RET rs1800858 polymorphism were observably higher in cases than controls, so is the role of rs74799832. This two polymorphisms were hardly reported in past years.

We have clarified RET rs1799939, rs1800858 and rs74799832 polymorphisms significantly increase TC susceptibility. In other words, RET polymorphisms maybe the risk predictors for developing aggressive of TC. This result has a positive influence on diagnosis and treatment of TC. But it may present some limitations due to neglecting environmental factors. Further study with well-design and enough large sample size is needed to assess the relationship of RET polymorphisms with TC susceptibility.

At the moment, the rapid increasing incidence of thyroid cancer in China has seriously harmed people’s health. We should promote the programs of general examination, early diagnosis and timely treatment as well as advocating healthy lifestyle and diet custom among high-risk population in high-prevalence areas. What is more, more efforts are made to explore the pathogenic gene of TC.

Disclosure of conflict of interest

None.

References

  • 1.Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9:421–427. doi: 10.1089/thy.1999.9.421. [DOI] [PubMed] [Google Scholar]
  • 2.Faam B, Ghaffari MA, Ghadiri A, Azizi F. Epigenetic modifications in human thyroid cancer. Biomed Rep. 2015;3:3–8. doi: 10.3892/br.2014.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164–2167. doi: 10.1001/jama.295.18.2164. [DOI] [PubMed] [Google Scholar]
  • 4.Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998;154:237–247. doi: 10.1007/978-3-642-46870-4_15. [DOI] [PubMed] [Google Scholar]
  • 5.Ivanov VK, Tsyb AF, Nilova EV, Efendiev VF, Gorsky AI, Pitkevich VA, Leshakov SY, Shiryaev VI. Cancer risks in the Kaluga oblast of the Russian Federation 10 years after the Chernobyl accident. Radiat Environ Biophys. 1997;36:161–167. doi: 10.1007/s004110050067. [DOI] [PubMed] [Google Scholar]
  • 6.Chow SM, Law SC, Au SK, Mang O, Yau S, Yuen KT, Lau WH. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000. Clin Oncol (R Coll Radiol) 2003;15:329–336. doi: 10.1016/s0936-6555(03)00066-9. [DOI] [PubMed] [Google Scholar]
  • 7.Sakoda LC, Horn-Ross PL. Reproductive and menstrual history and papillary thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev. 2002;11:51–57. [PubMed] [Google Scholar]
  • 8.Galanti MR, Sparen P, Karlsson A, Grimelius L, Ekbom A. Is residence in areas of endemic goiter a risk factor for thyroid cancer? Int J Cancer. 1995;61:615–621. doi: 10.1002/ijc.2910610506. [DOI] [PubMed] [Google Scholar]
  • 9.Aschebrook-Kilfoy B, Sabra MM, Brenner A, Moore SC, Ron E, Schatzkin A, Hollenbeck A, Ward MH. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid. 2011;21:957–963. doi: 10.1089/thy.2010.0396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kitahara CM, Platz EA, Beane Freeman LE, Black A, Hsing AW, Linet MS, Park Y, Schairer C, Berrington de Gonzalez A. Physical activity, diabetes, and thyroid cancer risk: a pooled analysis of five prospective studies. Cancer Causes Control. 2012 doi: 10.1007/s10552-012-9896-y. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer. 2009;16:1065–1072. doi: 10.1677/ERC-09-0150. [DOI] [PubMed] [Google Scholar]
  • 12.Zheng T, Holford TR, Chen Y, Ma JZ, Flannery J, Liu W, Russi M, Boyle P. Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935-1992. Int J Cancer. 1996;67:504–509. doi: 10.1002/(SICI)1097-0215(19960807)67:4<504::AID-IJC7>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  • 13.Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81:4318–4323. doi: 10.1210/jcem.81.12.8954034. [DOI] [PubMed] [Google Scholar]
  • 14.Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T, Machinami R. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract. 2000;196:1–7. doi: 10.1016/S0344-0338(00)80015-1. [DOI] [PubMed] [Google Scholar]
  • 15.Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455–6457. doi: 10.1038/sj.onc.1206739. [DOI] [PubMed] [Google Scholar]
  • 16.Bieche I, Franc B, Vidaud D, Vidaud M, Lidereau R. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid. 2001;11:147–152. doi: 10.1089/105072501300042802. [DOI] [PubMed] [Google Scholar]
  • 17.Rusinek D, Szpak-Ulczok S, Jarzab B. Gene expression profile of human thyroid cancer in relation to its mutational status. J Mol Endocrinol. 2011;47:R91–103. doi: 10.1530/JME-11-0023. [DOI] [PubMed] [Google Scholar]
  • 18.Goodfellow PJ, Wells SA Jr. RET gene and its implications for cancer. J Natl Cancer Inst. 1995;87:1515–1523. doi: 10.1093/jnci/87.20.1515. [DOI] [PubMed] [Google Scholar]
  • 19.Sovrea AS, Dronca E, Galatar M, Radian S, Vornicescu C, Georgescu C. Diagnostic correlation between RET proto-oncogene mutation, imaging techniques, biochemical markers and morphological examination in MEN2A syndrome: case report and literature review. Rom J Morphol Embryol. 2014;55:389–400. [PubMed] [Google Scholar]
  • 20.Schuchardt A, D’Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET . Nature. 1994;367:380–383. doi: 10.1038/367380a0. [DOI] [PubMed] [Google Scholar]
  • 21.Liu RT, Chou FF, Wang CH, Lin CL, Chao FP, Chung JC, Huang CC, Wang PW, Cheng JT. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese. Thyroid. 2005;15:326–335. doi: 10.1089/thy.2005.15.326. [DOI] [PubMed] [Google Scholar]
  • 22.Mukhopadhyay S, Pennell NA, Ali SM, Ross JS, Ma PC, Velcheti V. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. J Thorac Oncol. 2014;9:1714–1719. doi: 10.1097/JTO.0000000000000323. [DOI] [PubMed] [Google Scholar]
  • 23.Valdes N, Navarro E, Mesa J, Casteras A, Alcazar V, Lamas C, Tebar J, CastaNo L, Gaztambide S, Forga Llenas L. RET Cys-634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. Eur J Endocrinol. 2015;172:301–7. doi: 10.1530/EJE-14-0818. [DOI] [PubMed] [Google Scholar]
  • 24.Sosonkina N, Hong SK, Starenki D, Park JI. Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics. 2014;36:829–841. doi: 10.1007/s13258-014-0217-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Clin Endocrinol (Oxf) 2015;82:892–9. doi: 10.1111/cen.12686. [DOI] [PubMed] [Google Scholar]
  • 26.Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Incidence of thyroid cancer in Norway 1970-1985. Population review on time trend, sex, age, histological type and tumour stage in 2625 cases. APMIS. 1990;98:549–558. [PubMed] [Google Scholar]
  • 27.Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7. doi: 10.1007/s12022-007-0002-z. [DOI] [PubMed] [Google Scholar]
  • 28.Lkhoyaali S, Benhmida S, Ait Elhaj M, Layachi M, Bensouda Y, Errihani H. [Targeted therapy in thyroid cancer: Towards a treatment card] . Pathol Biol (Paris) 2015;63:1–6. doi: 10.1016/j.patbio.2014.11.003. [DOI] [PubMed] [Google Scholar]
  • 29.Lee YC, Chung JH, Kim SK, Rhee SY, Chon S, Oh SJ, Hong IK, Eun YG. Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population. Cytokine. 2015;71:283–288. doi: 10.1016/j.cyto.2014.11.011. [DOI] [PubMed] [Google Scholar]
  • 30.Wei WJ, Lu ZW, Li DS, Wang Y, Zhu YX, Wang ZY, Wu Y, Wang YL, Ji QH. Association of the miR-149 Rs2292832 polymorphism with papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese population. Int J Mol Sci. 2014;15:20968–20981. doi: 10.3390/ijms151120968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chen J, Liu C, Yin L, Zhang W. The tumor-promoting function of ECRG4 in papillary thyroid carcinoma and its related mechanism. Tumour Biol. 2015;36:1081–9. doi: 10.1007/s13277-014-2731-1. [DOI] [PubMed] [Google Scholar]
  • 32.Klugbauer S, Pfeiffer P, Gassenhuber H, Beimfohr C, Rabes HM. RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics. 2001;73:149–160. doi: 10.1006/geno.2000.6434. [DOI] [PubMed] [Google Scholar]
  • 33.Maenhaut C, Detours V, Dom G, Handkiewicz-Junak D, Oczko-Wojciechowska M, Jarzab B. Gene expression profiles for radiation-induced thyroid cancer. Clin Oncol (R Coll Radiol) 2011;23:282–288. doi: 10.1016/j.clon.2011.01.509. [DOI] [PubMed] [Google Scholar]
  • 34.Wiench M, Kwasniewski M, Gubala E, Wygoda Z, Pawlaczek A, Oczko M, Jarzab B. [Proto-oncogene RET somatic mutations in medullary thyroid carcinoma] . Wiad Lek. 2001;54(Suppl 1):415–421. [PubMed] [Google Scholar]
  • 35.Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, Berti P, Basolo F, Ugolini C, Ciampi R, Nikiforov Y, Pinchera A. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab. 2004;89:5823–5827. doi: 10.1210/jc.2004-0312. [DOI] [PubMed] [Google Scholar]
  • 36.Santos M, Azevedo T, Martins T, Rodrigues FJ, Lemos MC. Association of RET genetic polymorphisms and haplotypes with papillary thyroid carcinoma in the Portuguese population: a case-control study. PLoS One. 2014;9:e109822. doi: 10.1371/journal.pone.0109822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ceolin L, Siqueira DR, Ferreira CV, Romitti M, Maia SC, Leiria L, Crispim D, Ashton-Prolla P, Maia AL. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness. Eur J Endocrinol. 2012;166:847–854. doi: 10.1530/EJE-11-1060. [DOI] [PubMed] [Google Scholar]
  • 38.Ho T, Li G, Zhao C, Wei Q, Sturgis EM. RET polymorphisms and haplotypes and risk of differentiated thyroid cancer. Laryngoscope. 2005;115:1035–1041. doi: 10.1097/01.MLG.0000162653.22384.10. [DOI] [PubMed] [Google Scholar]
  • 39.Cardot-Bauters C, Leteurtre E, Leclerc L, Vantyghem MC, Do Cao C, Wemeau JL, d’Herbomez M, Carnaille B, Barbu V, Pinson S, Pigny P. Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma? Clin Endocrinol (Oxf) 2008;69:506–510. doi: 10.1111/j.1365-2265.2008.03230.x. [DOI] [PubMed] [Google Scholar]
  • 40.Lantieri F, Caroli F, Ceccherini I, Griseri P. The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study. Int J Cancer. 2013;132:2808–2819. doi: 10.1002/ijc.27967. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Clinical and Experimental Pathology are provided here courtesy of e-Century Publishing Corporation

RESOURCES